Patent · US Active

IRAK4 inhibitor and use thereof

US10562902B2 · kind B2 · utility

1Cited by

5References

6Claims

0Family size

Assignee

BEIJING HANMI PHARMACEUTICAL CO., LTD. · CN

Inventors

Jiangcheng XU · Beijing, CN
Qinguan Cai · Beijing, CN
Mi Young Cha · Beijing, CN
Maengsup Kim · Beijing, CN

Key dates

Filing date	Aug 12, 2016
Grant date	Feb 18, 2020
Priority date	—
Expiry date	Aug 12, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.